Sarepta Pops To 16-Year High As It Nears Approval In Muscular Dystrophy

Sarepta Therapeutics (SRPT) rocketed to a 16-year high Monday on the likelihood that its newest Duchenne muscular dystrophy drug could gain approval in 2019, two years ahead of expectations.

X The Food and Drug Administration said Monday it will allow Sarepta to use an increase in a protein called dystrophin as proof of the drug's effectiveness. Duchenne muscular dystrophy is caused by the absence of this protein, which keeps muscle cells intact. In afternoon trading on the stock market...

What feeling does this article give you?

#hashtags to follow:

Sarepta Therapeutics [+]    SRPT [+]    Monday [+]    Duchenne [+]   

More #news: